Netherlands Cancer Institute
- Address
- lock Available on a paid plan
Analytical, Diagnostic and Therapeutic Techniques and Equipment – Diagnosis
The Netherlands Cancer Institute is advancing diagnostic imaging and biomarker strategies to detect cancer earlier and more accurately. Researchers are integrating liquid biopsy and AI‑driven pathology to refine patient selection across tumor types.
- Development of PET/CT tracers for gastric cancer staging
- Validation of liquid biopsy for KRAS G12C detection
- Integration of AI for pathology review
- Optimization of non‑invasive biomarkers in lung cancer
- Assessment of imaging techniques for peritoneal metastases
With 62 active trials and over 100 investigators, the site focuses on improving early detection and precise disease monitoring to guide treatment decisions.
Analytical, Diagnostic and Therapeutic Techniques and Equipment – Therapeutics
A broad portfolio of studies evaluates novel therapeutic agents and combination regimens, aiming to enhance efficacy while maintaining safety for patients with advanced cancers.
- Antibody‑drug conjugates in urothelial carcinoma
- KRAS G12C inhibitors for solid tumors
- ALK inhibitors for NSCLC
- HER2‑targeted therapies in breast and gastric cancer
- CAR‑T approaches for CLDN6‑positive tumors
These trials seek to establish new standards of care by testing breakthrough drugs and immunotherapy combinations across multiple cancer types.
Analytical, Diagnostic and Therapeutic Techniques and Equipment – Surgical Procedures, Operative
Surgical innovation is paired with systemic therapy to improve resection outcomes and reduce postoperative morbidity. The institute evaluates both curative and organ‑preserving approaches.
- HIPEC combined with systemic chemotherapy for colorectal peritoneal metastases
- Neoadjuvant FOLFOXIRI for high‑risk rectal cancer
- Organ‑preserving surgery after immunotherapy in melanoma
- Minimally invasive techniques for renal cell carcinoma
- Surgical validation of intra‑operative imaging agents
The goal is to increase complete response rates and accelerate recovery, supporting patients through multimodal treatment pathways.
Diseases – Digestive System Diseases
Research targets malignancies of the gastrointestinal tract, exploring molecularly driven therapies and optimized chemoradiation protocols.
- Advanced gastric cancer with peritoneal spread
- Metastatic colorectal cancer with MSI‑H/dMMR
- Locally advanced rectal cancer
- Esophageal squamous cell carcinoma
- Gastroenteropancreatic neuroendocrine tumors
Trials aim to extend survival and improve quality of life by matching targeted agents to specific genetic alterations in digestive system cancers.
Diseases – Female Urogenital Diseases and Pregnancy Complications
The institute conducts studies on gynecologic and urinary tract cancers, emphasizing therapies that preserve fertility and reduce treatment‑related toxicity.
- Muscle‑invasive bladder cancer immunotherapy
- HER2‑positive ovarian cancer combinations
- Targeted therapy for urothelial carcinoma
- Radiotherapy alternatives for vulvar cancer
- Biomarker discovery in gynecologic malignancies
By integrating novel agents and precision diagnostics, these studies strive to achieve durable responses while maintaining patients’ quality of life.
Diseases – Neoplasms
A multi‑basket approach addresses a wide spectrum of solid tumors, linking specific molecular drivers to tailored treatments.
- KRAS G12C mutant solid tumors
- BRAF V600E melanoma
- RET‑mutant medullary thyroid cancer
- Dedifferentiated liposarcoma
- ALK‑positive NSCLC
These studies evaluate objective response rates and survival benefits, advancing personalized oncology for diverse neoplastic diseases.
Diseases – Respiratory Tract Diseases
Lung cancer research focuses on overcoming resistance mechanisms and optimizing immunotherapy sequences for both non‑small cell and small‑cell disease.
- EGFR‑mutated NSCLC after tyrosine kinase inhibitor failure
- KRAS G12C NSCLC
- ALK‑rearranged NSCLC
- Limited‑stage small‑cell lung cancer with atezolizumab
- Immunotherapy maintenance in advanced NSCLC
The objective is to prolong progression‑free and overall survival while maintaining tolerability for patients with respiratory tract malignancies.
Miscellaneous Research
Additional studies address rare tumors, advanced imaging, and novel therapeutic concepts that do not fit traditional categories.
- Targeted therapy for desmoid tumors
- Trials in thymic carcinoma and type B3 thymoma
- Investigational agents for gastrointestinal stromal tumors
- Radioligand therapy for neuroendocrine tumors
- Imaging biomarker development for gastric cancer staging
This flexible portfolio demonstrates the site’s capacity to explore emerging opportunities and address unmet clinical needs across oncology.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 18 therapeutic areas and 15 of 322 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 317 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 68 by active trials.
lock +67 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +45 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Netherlands Cancer Institute
lock Showing 1 of 327 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (Peak) A Phase 3 Randomized, Open-label, Multicenter Clinical Study of CGT9486+Sunitinib vs Sunitinib in Subjects with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors | Cogent Biosciences Inc. | Phase III | Not Recruiting | Mar 2023 | — |
IMP list
lock Showing 1 of 322 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 58 | Unknown | 2015-07-16 | 2026-07-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.